Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.

Shuyi WuMeina LvJiana ChenShaojun JiangMingrong ChenZongwei FangZhiwei ZengJiafen QianWenlin XuChengfu GuanJin-Hua Zhang

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)

For preventing and treating VTE, in terms of VTE occurrence and major bleeding, apixaban had the lowest risk; in terms of clinically relevant non-major bleeding, LMWH had the lowest risk, followed by apixaban. Generally, apixaban is the most efficient and safest DOAC and presents better efficacy and relatively low bleeding risk among the VTE prevention and treatment drugs for patients with cancer.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
combination therapy
replacement therapy
drug induced